Category: Vaccine

Page 149«..1020..148149150151..160170..»

Moffitt Study Aims to Improve Personalized Cancer Vaccines | Moffitt – Moffitt

November 6, 2023

Gibe.LinkPicker.Umbraco.Models.LinkPicker

By Kim Polacek, APR, CPRC - November 05, 2023

Personalized cancer vaccines to treat cancer are an emerging area of cancer research. This type of therapy engages the immune systems cells to attack a tumor by exposing them to unique proteins or antigens expressed by a cancer cell. The vaccines have shown promise in the treatment of solid tumor malignancies, but there continues to be a need to optimize this complex therapeutic approach.

Moffitt Cancer Center researchers are working to improve the efficacy of neoantigen-targeted cancer vaccines by better understanding whether primary or metastatic tumors should be used to produce the personalized vaccine. They launched a study evaluating primary and metastatic tumors pairs from 45 patients with several solid tumor types, including melanoma, bladder, head and neck cancers, and non-small cell lung cancer. Whole exome sequencing was used to identify somatic alterations, which are genetic mutations or DNA alterations that may impact the type of antigens produced by the cancer cells that can then be targeted by the vaccine.

Results presented at the Society for Immunotherapy of Cancer annual meeting show that melanoma, bladder and head and neck tumors share a high percentage of mutations between primary and metastatic tumors. However, other solid tumors, such as esophageal and non-small cell lung cancer, share less.

Our analysis demonstrates genetic variations that exist when comparing paired primary and metastatic tumors that appear to vary by histology. Variants are potentially undergoing negative selection supported by the preferential loss of out-of-frame events in metastatic tumors,saidDr. Ahmad Tarhini, senior member in the Departments of Cutaneous Oncology and Immunology and director of Cutaneous Clinical and Translational Research at Moffitt. Understanding the clonal structure will be key to neoantigen prediction for effective neoantigen-based vaccines where oncogenic drivers can be prioritized and used to determine the primary clones.

Tarhini and the Moffitt team are continuing this work, expanding their study to include paired tumor samples from 600 additional patients.

See the rest here:

Moffitt Study Aims to Improve Personalized Cancer Vaccines | Moffitt - Moffitt

Sustaining COVID-19 vaccine and routine immunization uptake in … – WHO | Regional Office for Africa

November 6, 2023

When COVID-19 vaccination was introduced in Ghana, Gershon Kwame Osei, a religious leader from Ave-Dakpa Community in the Akatsi North District of Ghanas Volta region was one of the influential voices against the vaccine due to myths and superstition.

Now, his advocacy and social mobilization work along with many others is generating demand and driving people towards taking the COVID-19 vaccination. Osei is one of 900 community-based volunteers (CBVs) trained by the Ghana Coalition of NGOs in Health (GCNH) working in collaboration with the Ghana Health Service and the World Health Organization (WHO).

Thanks to the work of the community volunteers, over 80 000 people were vaccinated over the three-month, between 01 May to 31 July 2023, with about half receiving their COVID-19 vaccine for the first time.

Initially, I told my congregants not to take the vaccine because I was hearing that it is making people sick, says Osei. I am now well informed and happy to be helping to mobilize my people for their vaccination.

Health authorities in the Volta region were concerned about the slow COVID-19 vaccine uptake, with fears that the declassification of COVID-19 as a public health emergency will lead to a further decline in vaccination.

Community members question us on why we continue to administer the COVID-19 vaccination despite the declaration of the pandemic as no more constituting a public health emergency. This is negatively impacting vaccination coverage, says Dr Senanu Kwesi Djokoto, the Deputy Director for Public Health in the Volta Region.

The region is among low-performing regions in Ghana with only about two in every 10 of the general population completing primary series of COVID-19 vaccination compared with the national average of three in 10 as at the end of April 2023.

As part of efforts to help Ghana sustain the vaccination drive, WHO with funding from the Government of Canada through the Canada Grant for Vaccine Equity (CanGIVE) and Gavi, the Vaccine Alliance, engaged the GCNH, a non-state actor with representation in all regions to undertake advocacy, communication, and social mobilization in all districts and communities of the Volta region. The main objective was to dispel myths and generate demand for COVID-19 vaccination and routine immunization.

Although COVID-19 is no more a public health event of international concern, the virus continues to circulate and could come back stronger to cause devastation as observed in previous waves of the pandemic, says Prof Francis Kasolo, the WHO Representative to Ghana. We need to sustain the gains, modify the approach to demand generation, and ensure those who need the vaccine, especially persons in the high-risk groups receive them.

The trained community-based volunteers (CBVs) carried out interpersonal communication within the communities and leveraged soccer games to bring the youth together for vaccination. WHO provided technical support to vaccination teams to undertake house-to-house vaccination exercises along with the social mobilization efforts of volunteers.

I thought the virus was no more, so I did not want to go back and take the vaccine. But my encounter with the volunteers has motivated me and I have just taken a third dose, noted Christine Galley, a resident of Ave-Dakpa.

Health workers are confident of the impact of the intervention as COVID-19 vaccination uptake has improved by at least 20% since the rollout of the GCNH project. The intervention has also strengthened community engagement and delivery of other health services.

Community members are demanding other services in addition to COVID-19 vaccination. We leverage the support from this intervention to provide routine immunization, non-communicable disease screening, healthy lifestyle counselling, and distribution of family planning commodities says Prosper Amegadzie, a disease control officer working in Ho Municipal.

Ongoing efforts are already boosting the integration of routine vaccination and other health services with COVID-19 vaccination as sustainable and cost-effective, drawing on the synergies to restore routine immunization coverages to levels before the pandemic, while sustaining the uptake of COVID-19 vaccine.

See more here:

Sustaining COVID-19 vaccine and routine immunization uptake in ... - WHO | Regional Office for Africa

$25 Million Funds Arenavirus Vaccine Research Precision … – Precision Vaccinations

November 6, 2023

(Precision Vaccinations News)

The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford announced the launch of a new project to initiate early development of prototype vaccines against the Junn virus.

CEPI confirmed on October 2, 2023, that it would provide up to $25 million to Oxford for preclinical and Phase I clinical development of a vaccine against the Junn virus using Oxford's ChAdOx platform

This seldom-discussed virus was selected as an exemplar of the Arenavirus family, which includesthe Lassa virus, Junin virus, Machupo virus, Guanarito virus, and lymphocytic choriomeningitis virus.

Arenavirusinfections are responsible for multiple deadly hemorrhagic fevers with epidemic and pandemic potential. Junn virus can cause Argentine Haemmorhagic Fever, with symptoms including muscular pain, dizziness, rashes, and a 15-30% case fatality.

Dr. Richard Hatchett,CEO of CEPI, commented in a press release, "This new project will harness the University of Oxford's extensive vaccinology experience and its innovative ChAdOx vaccine technology one of only a handful of vaccine platforms proven to work at speed, scale, and low cost to expand the world's scientific knowledge on arenavirus vaccines."

"The project will generate vital resources for the proposed Global Vaccine Library, helping accelerate efforts to reduce vaccine development timelines to 100 days when faced with future threats."

The data and materials generated by this new project could give the world a head start in rapidly developing safe and effective vaccines against Arenaviruses within 100 days of their identification, potentially stopping a future pandemic in its tracks, wrote CEPI.

Read this article:

$25 Million Funds Arenavirus Vaccine Research Precision ... - Precision Vaccinations

Pfizer RSV vaccine gets off to fast start on market – BioPharma Dive

November 6, 2023

Dive Brief:

Pfizer had braced for a steep decline in revenue from its COVID products Comirnaty and Paxlovid. Still, the pharma didnt expect demand to drop off as much as has happened in the U.S. The company is now banking on the rest of its infectious disease portfolio to help compensate.

RSV vaccine sales are expected to pick up some of the slack. Pfizers Abrysvo gained clearance from the Food and Drug Administration in May, just a couple of weeks after a rival shot from Bristish drugmaker GSK gained approval in older adults. GSK is scheduled to announce new sales numbers for its vaccine, called Arexvy, on Wednesday.

So far, Pfizer has been pleased with Abrysvos early performance on the market. The shots launch is a contributing factor to the companys non-COVID operational revenue growth, which rose by 10%.

However, Pfizer believes the shot will contribute even more revenue, as it is the only approved RSV vaccine with clearance in maternal immunization.

Sanofi and partner AstraZeneca have an antibody shot, Beyfortus, that is approved for use in newborns to protect against RSV. But earlier this month, the Centers for Disease Control and Prevention asked physicians to ration it to higher-risk infants amid a supply shortage. Due to a limited supply, the CDC has asked doctors to conserve 100mg doses or recommend another RSV antibody, Synagis, in eligible newborns.

Additionally, the CDC is now encouraging pregnant people receive Pfizers shot. Abrysvos maternal guidance has a short window of use, though. The CDC recommends it for pregnant people between 32 and 36 weeks gestation from September through January to align with RSV season.

In Tuesdays earnings call, Pfizer said Abrysvo will be available in multiple settings such as pharmacies, OBGYN offices and doctor offices for both older adult and maternal immunization. And with the winter season coming up, the company expects to see good uptake.

Pfizer is continuing to prepare for other launches in its infectious disease portfolio including Prevnar 20 and its mRNA flu vaccine. The flu candidate, originally predicted to launch next year, is now expected to enter the market after 2024.

Read more:

Pfizer RSV vaccine gets off to fast start on market - BioPharma Dive

CK Public Health trying to restore confidence in all vaccines after … – CK News Today

November 6, 2023

Chatham-Kent Public Health is reporting that general vaccine hesitancy appears to be at a high amongstlocal residents following the COVID-19 pandemicand a new vaccination campaign is trying to address the problem.

Infectious Disease and Emergency Management Program Manager Marnie Van Vlymen saidimmunization of all infectious diseases must bea priorityin 2023/2024.

She said the public experienced vaccine fatigue during the pandemic and as a result the team has been and will continue to place their focus on increasing vaccine confidence inthe community.

Van Vlymennoted thatroutine vaccines for the many residents without a primary healthcare professional is also a priority and work on this issue will continue into 2024.

"Throughout 2023, COVID-19 vaccine administration has been a priority in accordance with the vaccine booster and guidance schedules provided by the ministry. The COVID-19 Vaccine Team will prioritize the administration of the 2023 Fall Booster to the identified high-risk population through October and will move to administration to the general public throughout November and December," said Van Vlymen.

CK Public Health officials noted vaccines will be available to the public through health unit-based clinics, flu and COVID-19 clinics in partnership with family health teams, and through pharmacies.

Click here for more details about the fall vaccination campaign and to book your appointment.

Excerpt from:

CK Public Health trying to restore confidence in all vaccines after ... - CK News Today

Ranger sues after being fired for COVID-19 vaccination refusal – Whidbey News-Times

November 6, 2023

An ex Deception Pass State Park ranger is suing the state for firing him after refusing the vaccine.

A former park ranger who worked at Deception Pass State Park is suing the state for allegedly firing him because he refused to get a COVID-19 vaccination.

Benjamin Shook recently filed a complaint in Island County Superior Court for declamatory relief and damages against the Washington State Parks and Recreation Commission. Shook, who is represented by Spokane Valley attorney Jung Hwang, claims State Parks violated a state discrimination law.

Shook asks to be compensated for financial losses. The claim states that he should have been placed on paid leave and should still be on paid leave.

The lawsuit notes that the park required, under Gov. Jay Inslees proclamation, that all employees be vaccinated by Oct. 18, 2021. It claims that Shook, an 18-year employee, sought and obtained an exemption from the vaccine requirement on religious basis but was nevertheless informed that he needed to be vaccinated or be fired.

The complaint states that State Parks refused to accommodate, retaliated against, and subsequently terminated Mr. Shook because he asked for an accommodation for his sincerely held religious beliefs.

Specifically, the claim states, Shook believed it was his religious duty to refuse experimental vaccines that utilize human cell lines from products of abortion during any stage of the vaccines development, including the testing phase.

While the COVID vaccines were not considered to be experimental and do not contain fetal tissue, cell lines developed from abortions in the 1970s were used in the testing or development of certain COVID-19 vaccines, according to the National Institute of Health and the Associated Press.

According to the lawsuit, Shook suggested an accommodation of a self-evaluation questionnaire before work every day, social distancing and masking, and periodic testing at (his) own expense, all of which were the standard practice before the governors mandate. State Parks, however, refused the accommodation, the lawsuits claims.

In addition to damages, the lawsuit asks for declaratory relief that a faith-based person who cannot be vaccinated cannot unilaterally be deemed physically unfit for the park ranger profession.

The state Attorney Generals Office has not yet filed an answer to the complaint. State Parks did not respond to a request for comment.

Continued here:

Ranger sues after being fired for COVID-19 vaccination refusal - Whidbey News-Times

36 Yellow Fever Deaths Confirmed in Africa Precision … – Precision Vaccinations

November 6, 2023

(Precision Vaccinations News)

According to an update recently published by theAfrica Centres for Disease Control and Prevention (Africa CDC), yellow fever outbreaks continueacross the continent in 2023.

As of October 28, 2023, the Africa CDC reported a total of 2,779 yellow fever cases, and 36 deaths (CFR: 1.3%)have been reported in seven African Union countries this year.

The impactedcountries are Cameroon (41 cases; 4 deaths), CAR (326; 5), Congo (324; 2), Gabon (79; 0), Guinea (178; 4), Nigeria (1,819; 21), and Uganda (12; 0).

In 2022, 12 countries in the African Regionreported confirmed yellow fever cases.

Yellow fever is an epidemic-prone, vaccine-preventable disease transmitted to humans by mosquitoes. The incubation period ranges from 3 to 6 days. While many people do not experience symptoms, individuals can have more severe symptoms.

Death can occur within 7 - 10 days in about half of cases with severe symptoms.

According to the WHO/UNICEF Estimates of National Immunization Coveragein 2021, routine immunization coverage against yellow fever in the African Region for childhood vaccinations was 48%, much lower than the threshold required to confer population immunity.

In reaction to these data, the WHO and Africa CDCre-assessed the health risk at the regional level in 2022 as moderate.

Currently, the U.S. population is mostly unvaccinated against yellow fever, andthe U.S. Strategic Stockpile has not secured vaccine reserves.

During a sizable epidemic in the U.S., the demand for yellow fever vaccines could surpass production capacities. Sanofi Pasteur'sYF-VAXvaccineis the only U.S. Food and Drug Administration-approved vaccine as of November 2023.

For many international travelers, proof of yellow fever vaccination is a requirement to visit at-risk countries, such as Brazil.

Link:

36 Yellow Fever Deaths Confirmed in Africa Precision ... - Precision Vaccinations

Merck Concealed Problems with Gardasil HPV Vaccine, Lawsuit … – AboutLawsuits.com

November 6, 2023

The product liability lawsuits claim Merck did this in a variety of ways, including using a highly toxic placebo during small clinical trials to hide the true rate of Gardasil injuries and complications, manipulating study protocols, and claiming serious side effects that occurred during the clinical trials among many of the participants were coincidences.

According to Makkis lawsuit, neither he nor his doctors knew the true risks of Gardasil when he received his first HPV vaccination in August 2019, when he was 35. He had agreed, on the advice of his doctor, to receive the vaccine for the prevention of the HPV virus. He received his second shot the next month, and a third injection in February 2020.

After the injections, Makki began to experience extremely painful and incapacitating headaches which prevented him from doing many daily activities, the lawsuit indicates. The migraines worsened over time, and he also began to experience anxiety attacks, short-term memory loss, insomnia, dizziness, vertigo, numbness and tingling in his extremities, photophobia and hair loss.

He has been diagnosed with autonomic dysfunction, migraines, alopecia, and telogen effluvium, according to the lawsuit.

Makki indicates the medical community, and the U.S. Food and Drug Administration, were deceived by Merck during both the drugs development and approval, and marketing.

Merck engaged in wholesale fraud during its safety and efficacy clinical studies. In order to obtain its Gardasil license, Merck purposefully conducted its studies to conceal adverse events and exaggerate efficacy, the lawsuit states. The dishonesty in the clinical tests has led many physicians to recommend the vaccination, under false assumptions.

The lawsuit claims Merck kept some of its clinical trial results secret, and injected control subjects with a placebo that contained a toxic adjuvant; an ingredient used to create a stronger immune response, which led to similar injuries in both groups. Merck presented those findings as indications Gardasil was as safe as a placebo without mentioning use of the adjuvant, according to Makkis complaint.

Those results included increased death rates among recipients of the drug, an increase in fertility problems after Gardasil vaccination, as well as other injuries. These problems have resulted in several countries removing their recommendations, including Japan and Columbia. In addition, Denmark has opened specialized clinics dealing with Gardasil injuries, and India put a stop to Gardasil trials in its own country after several female subjects died, the lawsuit claims.

However, the lawsuit indicates Merck has still profited handsomely off the Gardasil vaccine, pulling in $6.9 billion in revenue from the injections in 2022. Two doses of the latest iteration, Gardasil 9, costs about $450.

Makkis complaint will be consolidated with about 100 other similar lawsuits over the Gardasil HPV vaccine currently pending in the federal court system, which have been centralized as part of a Gardasil MDL (multidistrict litigation)in the U.S. District Court for the Western District of North Carolina.

There are also a substantial number of additional claims pending in the U.S. Vaccine Court, where families must initially bring a petition seeking compensation under the National Vaccine Injury Compensation Program, before they are able to bring a civil lawsuit if the claim is not resolved within eight months.

Given common questions of fact and law presented in the HPV vaccine lawsuits, U.S. District Judge Robert J. Conrad is presiding over coordinated discovery and pretrial proceedings, which is expected to involve a series of early bellwether trials designed to help gauge how juries are likely to respond to certain evidence and testimony that will be repeated throughout the litigation.

While the parties work to prepare agroup of Gardasil cases for trial, injury lawyers are continuing to investigate and file new lawsuits for individuals who experienced a variety of complications from the HPV vaccine, including:

Following coordinated discovery and any bellwether trials in the federal MDL, if the parties fail to reach Gardasil settlements or another resolution for the litigation, Judge Conrad may later establish a process to begin remanding each individual claim back to U.S. District Courts nationwide for individual trial dates in the future.

The rest is here:

Merck Concealed Problems with Gardasil HPV Vaccine, Lawsuit ... - AboutLawsuits.com

Travis Kelce and the trap of celebrity vaccine endorsements – STAT – STAT

November 3, 2023

Once the domain of aging TV stars, hawking health products from vitamins to diabetes supplies to a geriatric demographic, A-list celebrity endorsements of health care products are positively trendy. Migraine sufferer Lady Gaga has a deal with Nurtec ODT, a prescription drug that treats migraines from pharma company Pfizer. This Is Us actor Mandy Moore is contracted by Incyte to promote Opzelura, an eczema treatment. Now Kansas City Chiefs tight end Travis Kelce, who is making headlines as Taylor Swifts current paramour, is the latest and buzziest pharma spokesperson. In a campaign promoted by Pfizer, he encourages people to get a twofera Covid shot and flu shot at the same time.

But theres a problem here for Kelce and Pfizer (and its not Jets QB and anti-vaxxer Aaron Rodgers trash talking): Celebrity endorsements to promote health behavior change dont work, at least not in the way you might think.

Selling health is not the same as selling shoes. Classic research in health campaign design shows that tactics used to effectively promote health behaviors are not the same as ones used to sell us on the newest and greatest consumer goods.

Health is a highly personal and private issue. Our health encompasses all our fears and frailties as well as our quality of life. HIPAA supports our concern that highly personal aspects about us in the wrong hands, could affect our lives, from employment to insurance coverage and more.

Research has shown that when it comes to our health, motivating behavior change is a difficult thing. Essentially, if were not already doing the behavior by choice, it is difficult to convince us to do something different. We tend to downplay, discredit, or even ignore suggestions that run contrary to our current behaviors and interests, even to our own detriment.

Of course, the medical community is constantly striving to come up with new ways to reach this stubborn-to-change market. In the case of vaccines that save lives, its imperative to reach those who are hesitant. However, this audience is highly suspicious and resistant to being sold on something, whether a pill or a vaccine. Persuading them to make a health behavior change is Sisyphean.

But not impossible. The message must discuss the benefits the action will provide, as well as effectively reduce objections and increase their confidence of successfully engaging in the behavior change. More importantly, all of this must be done by a credible source who this audience trusts. They must believe the spokesperson understands health and medicine. Fail on any of these points and you lose the consumer. Health messaging designed to change health behaviors is unforgiving.

Celebrities rarely satisfy any of these criteria. Sure, one of Lady Gagas Little Monsters who suffers from migraines might consider Nurtec because the singer publicly stated the drug helped her overcome her migraines. Similarly, a Mandy Moore fan with eczema who is struggling with treatment could give Opzelura a try since, like Gaga, Moore has firsthand experience with the condition. However, in both these scenarios, the key is that they are dealing with consumer choice, not consumer behavior change. In cases like these, consumers are already inclined towards the health action being advertised and the celebrities are serving to influence their choice of products, often effectively.

However, you cant argue Gaga or Moore are medical experts. Nor should consumers trust celebrities to be a credible source for health information. These are important qualities in cases where health behavior change is being attempted. Travis Kelces presence in a vaccine commercial potentially makes people aware of the idea of getting the Covid and flu shots at the same time, which public health officials are promoting. However, his endorsement wont change the minds or behaviors of anyone undecided or against them. It serves merely as a reminder or reinforcement for those who were already going to get the vaccine.

In contrast, anti-vaxxers will perceive Kelces presence as confirmation that vaccines are a bad decision, particularly around this politically polarized public health issue. More importantly, the group that is of primary concern, the undecided, will see the commercial and move on, minds unchanged. What does a tight end know about vaccines?

The result of the costly ad: The celebrity reinforced the action of those who were already going to do the behavior, entrenched those even more who were against the behavior, and was ignored by those who were the actual focus of the commercial in the first place. Indeed, the promo did nothing to boost Pfizers bottom line. The pharma company lost more than $2 billion in the third quarter due to lackluster sales of their Covid products.

In addition, celebrity endorsements potentially bring unwanted baggage to a health issue that cannot afford negative press. Celebrities tend to attract two groups of people: fans who adore them, and critics who live to attack them. While using a celebrity for a health issue endorsement might bring positive views by fans, its still not enough to engage behavior change if those fans arent already in the pro camp. Health issues are simply too complicated and too personal. Fans will still separate feelings for the celebrity from their decision to engage in a healthy behavior.

This is often reversed in cases of critics with negative views. Rather than separating the negative feelings from the health product, the negative views of the celebrity transfer to the advertised product, compounding the already existing adverse feelings about engaging in the specific health action. Now these anti groups have additional justification to shun a health behavior or product.

Health messaging is already difficult enough. Unfortunately, in the classic case of if it isnt broke, dont fix it, medical advertisers are using the same celebrity tactics that have proven successful in product and service advertising. Despite best intentions, this tactic fails to move the needle, so to speak, when it comes to creating health behavior change. At best, these celebrity endorsements serve as alerts, making audiences aware of an issue, but they dont change minds or, more importantly, actions. At worst the ads provide additional justifications for those who dont want to adopt the health behavior change to avoid the issue or product altogether. Given that celebrity endorsements are an expensive investment, medical organizations should pause and consider what they are truly paying for. Not even Taylor Swift can persuade anti-vaxxers to get the jab.

Christopher Morse, Ph.D., is professor and chair of the Department of Communication and Language Studies at Bryant University.

Read more:

Travis Kelce and the trap of celebrity vaccine endorsements - STAT - STAT

COVID vaccine misinformation has lowered confidence in other shots – The Philadelphia Inquirer

November 3, 2023

A steady flow of misinformation about COVID-19 and its vaccines has weakened public confidence in long-established vaccines that protect against other diseases, University of Pennsylvania researchers said Thursday, citing a new national survey.

In the October survey of 1,559 people by Penns Annenberg Public Policy Center, just 71% agreed with the statement vaccines approved for use in the U.S. are safe despite overwhelming evidence for their safety down from 77% in April 2021.

The decline threatens to erode decades of hard-won public health protections, center director Kathleen Hall Jamieson said.

Im generally an optimist, and this survey calls into question that disposition, she said.

She blamed the decline on a conservative ecosystem that sought to undermine the credibility of public health experts encouraging Americans to get the COVID vaccine, such as CDC officials and Anthony Fauci, the former White House chief medical advisor.

Republicans are less likely than Democrats to get the COVID vaccines, polling by KFF has found. Still, anti-vaccine messaging is not limited to conservatives. Robert F. Kennedy Jr., who is running for president as an independent, has long faced criticism for spreading unscientific claims about vaccines.

Weve had extended, ongoing discourse attacking vaccination by voices that had credibility with certain audiences, she said.

The decline in vaccine confidence in the new Penn survey was statistically significant, meaning that if surveyors were to redo the survey 20 times, polling similarly representative samples of the U.S. population, they would expect to see such a decline in 19 of those 20 cases.

In addition to the question about the safety of all vaccines, the survey included questions about the perceived safety and effectiveness of individual vaccines. Public confidence in several of them declined in little over a year, despite decades of evidence supporting their use, pollsters found.

When asked about the vaccine against measles, mumps, and rubella, for example, 8% said the shot was very or somewhat ineffective, up from 4% in August 2022. Asked about the safety of that vaccine, 9% said it was very or somewhat unsafe, up from 6% a year earlier.

The same trend held true in several questions about the COVID vaccines.

Asked to evaluate the statement its safer to get the COVID19 vaccine than to get COVID19, 21% of those surveyed said it was definitely or probably false, up from 16% a year ago and 10% in April 2021.

For Jamieson, the most worrisome figure was the 71% who agreed that approved vaccines are safe. To prevent outbreaks of disease, vaccines typically must be administered to more than 90% of the population. Surveyors did not ask whether respondents had gotten various vaccines, but in the past, they have found that perceptions of a vaccines safety are strongly correlated with willingness to get it.

She said one strategy to counter unscientific views is to enlist credible spokespeople outside the public-health realm.

Youre looking for your athletes, your celebrities, anybody whose credibility has not been undermined, she said.

The survey was conducted for the Annenberg Center by SSRS, an independent market research company.

Here is the original post:

COVID vaccine misinformation has lowered confidence in other shots - The Philadelphia Inquirer

Page 149«..1020..148149150151..160170..»